Human Gene Therapy

Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.

Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.

HGT publishes 12 double issues per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The journal also publishes a wide range of reviews, commentaries and editorials.

• Basic and clinical advances in gene therapy
• Delivery systems
• Cell therapy
• Immunotherapy
• Clinical genome editing
• Small nucleic acid therapeutics, including RNAi
• Clinical trials (including confirmatory or negative results)
• Improvements in vector developments
• Animal models
• Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products
• Clinical protocols
• Commercial development of gene and cell therapy products

Human Gene Therapy was the first journal devoted to cover the field of gene therapy.

Human Gene Therapy is under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School and other leading investigators. View the entire editorial board.

Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others.

Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance